WASHINGTON — A drug pricing advocacy group on Thursday announced a roughly $1 million ad campaign to boost a Trump administration proposal to align American drug prices with those in other wealthy nations, providing an outside boost to a policy concept that the drug industry has vocally opposed.

The same advocacy group, Patients for Affordable Drugs, spent $10 million via its political arm to endorse midterm election candidates it said were working to lower drug costs — and to oppose candidates it said were in bed with industry.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

  • It is amusing how the real Americans “don’t want foreign countries setting our drug prices”, although it is not clear why it would be such a despicable thing. And, on the other hand, they are perfectly fine with Russia manipulating US elections and politics

  • The US medical drug supply chain from drug maker to patient contributes substantially to the “cost of drugs” in the USA. Cut out a huge chunk of the interim handlers and their “incentive discounts”, put curbs on the extravagant advertising and lobbying allowances, and the cost would foreseeably come down dramatically.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy